首页
期刊导航
期刊检索
论文检索
新闻中心
期刊
期刊
论文
首页
>
《中华医学杂志(英文版)》
>
2020年20期
>
Combination therapies with mitogen-activated protein kinase kinase inhibitors and immune checkpoint inhibitors in non-small cell lung cancer
Combination therapies with mitogen-activated protein kinase kinase inhibitors and immune checkpoint inhibitors in non-small cell lung cancer
打印
分享
在线阅读
下载PDF
导出详情
摘要
无
DOI
ojzywk3e45/4907922
作者
Xu Jia-Li
Wang Xin-Zhu
Jiang Hu-Ning
Chen Yi
Wang Rong
Shu Yong-Qian
机构地区
Department of Oncology, The First Affiliated Hospital of Nanjing Medical University, Nanjing, Jiangsu 210029, China,First Clinical Medical College, Nanjing Medical University, Nanjing, Jiangsu 210029, China
出处
《中华医学杂志(英文版)》
2020年20期
关键词
分类
[医药卫生][]
出版日期
2020年11月08日(中国期刊网平台首次上网日期,不代表论文的发表时间)
相关文献
1
Li Wen-Qian,Li Ling-Yu,Bai Ri-Lan,Qian Lei,Chen Nai-Fei,Cui Jiu-Wei.
Cost-effectiveness of programmed cell death ligand 1 testing and tumor mutational burden testing of immune checkpoint inhibitors for advanced non-small cell lung cancer
.医药卫生,2020-11.
2
Jiayi Deng,Ming Gao,Qing Gou,Chongrui Xu,Honghong Yan,Mingyi Yang,Jiakang Li,Xiaorong Yang,Xuewu Wei,Qing Zhou.
Organ-specific efficacy in advanced non-small cell lung cancer patients treated with first-line single-agent immune checkpoint inhibitors
.医药卫生,2022-12.
3
Li Chu-Ling,Song Yong.
Combination strategies of immunotherapy in non-small cell lung cancer: facts and challenges
.医药卫生,2021-09.
4
Cheng Ying,Li Hui,Zhang Liang,Liu Jing-Jing,Yang Chang-Liang,Zhang Shuang.
Current and future drug combination strategies based on programmed death-1/programmed death-ligand 1 inhibitors in non-small cell lung cancer
.医药卫生,2021-08.
5
Qian Fang-Fei,Han Bao-Hui.
Mechanisms of resistance to immune checkpoint inhibitors and strategies to reverse drug resistance in lung cancer
.医药卫生,2020-11.
6
LIANG Wei-hong BI Jia-jia PENG Wei-feng ZHANG Fan SHI Hong-hao LI Li.
Cloning and Expression Analysis of a Mitogen-Activated Protein Kinase Gene OsMPK14 in Rice
.作物学,2010-04.
7
Zhou Fei,Zhou Cai-Cun.
Immunotherapy in non-small cell lung cancer: advancements and challenges
.医药卫生,2021-05.
8
Shi Wen-Jia,Zhao Wei.
Biomarkers or factors for predicting the efficacy and adverse effects of immune checkpoint inhibitors in lung cancer: achievements and prospective
.医药卫生,2020-11.
9
Yu-Sook Jeong;Hye-Suk Han;Sung-Nam Lim;Mi-Jin Kim;Joung-Ho Han;Min-Ho Kang;Dong-Hee Ryu;Ok-Jun Lee;Ki-Hyeong Lee;Seung-Taik Kim.
Gallbladder Metastasis of Non-small Cell Lung Cancer Presenting as Acute Cholecystitis
.肿瘤,2012-03.
10
Siyuan Ren,Mengyao Ma,Chuan He,Yuhui Deng,Xiaoyun Chen,Yonglin Liu,Yangyang Jin,Yansong Liu,Lei Cai,Lin He.
Placebo effect in the treatment of non-small cell lung cancer: a meta-analysis
.医药卫生,2022-12.
来源期刊
中华医学杂志(英文版)
2020年20期
相关推荐
Immune checkpoint inhibitors-associated cardiotoxicity in immunotherapy trials on gastrointestinal cancer patients
Fueling the engine and releasing the break: combinational therapy of cancer vaccines and immune checkpoint inhibitors
Expression and Prognostic Significance of Multidrug Resistance Associated Protein (MRP) Gene in Non-small Cell Lung Cancer by in Site Hybridization
Type 1 diabetes induced by immune checkpoint inhibitors
FDA expands approval of Imfinzi to reduce the risk of non-small cell lung cancer progressing
同分类资源
更多
[医药卫生]
一种粪便收集装置的设计
[医药卫生]
乳腺癌患者专用病号服的设计与应用
[医药卫生]
ICU获得性衰弱患者整合性照护临床应用的研究进展
[医药卫生]
卒中相关睡眠障碍评估工具的研究进展
[医药卫生]
患者赋权的概念分析
相关关键词
返回顶部